- €677.78m
- €638.43m
- $245.32m
- 54
- 19
- 31
- 24
Annual income statement for Pharming NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 189 | 212 | 199 | 206 | 245 |
| Cost of Revenue | |||||
| Gross Profit | 165 | 189 | 178 | 188 | 220 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 121 | 136 | 185 | 187 | 251 |
| Operating Profit | 68.2 | 76.3 | 13.6 | 18.2 | -5.39 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 52.2 | 44.1 | 23.1 | 15 | -12 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 40.5 | 37.7 | 16 | 13.7 | -10.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 40.5 | 37.7 | 16 | 13.7 | -10.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 40.5 | 37.7 | 16 | 13.7 | -10.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.059 | 0.055 | 0.038 | 0.009 | -0.032 |
| Dividends per Share |